In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

1. Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026
   Article
2. Recent advances in understanding the spectrum of genetic determinants of lipoprotein(a) levels.Current opinion in lipidology · 2026
   Review
3. Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025
   Review
4. 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025
   Article
5. Nanopore sequencing with unique molecular identifiers enables accurate mutation analysis and haplotyping in the complex lipoprotein(a) KIV-2 VNTR.Genome medicine · 2024
   Article
6. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Journal of the American Heart Association · 2024
   Review
7. Oxidized phospholipids in cardiovascular disease.Nature reviews. Cardiology · 2024
   Review
8. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
9. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.European heart journal · 2022
   Article
10. Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes.Journal of thrombosis and thrombolysis · 2022
    Article
11. Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry.Circulation. Genomic and precision medicine · 2021
    Article
12. Lipoprotein(a) and PCSK9 inhibition: clinical evidence.European heart journal supplements : journal of the European Society of Cardiology · 2020
    Article
13. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.The American journal of cardiology · 2020
    Review
14. Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease-a comparison in the MONICA/KORA study.Cardiovascular diabetology · 2020
    Article
15. Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk.International journal of chronic diseases · 2020
    Review
16. Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography.Journal of atherosclerosis and thrombosis · 2019
    Review
17. Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians.Indian heart journal
    Review

Corrections and comments

• Comment on
  2018

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as